N
Nkarta Therapeutics
Nkarta Therapeutics is a biotech company
About Nkarta Therapeutics
Nkarta is a biotechnology company focused on developing next-generation cell therapies to treat cancer and autoimmune diseases. Utilizing proprietary NK (natural killer) cell expansion technology pioneered by Dario Campana, Nkarta enhances the pathogen-fighting capabilities of these immune cells to search and destroy tumor cells more effectively. The company operates in the biopharmaceutical market, targeting patients with life-threatening conditions. Nkarta's business model revolves around research and development, clinical trials, and eventual commercialization of its cell therapy products. Revenue is generated through partnerships, licensing agreements, and future product sales. The company serves a diverse range of clients, including healthcare providers, research institutions, and patients. Nkarta aims to improve the efficacy, tolerability, and accessibility of cell therapies, making them more potent and rapidly available to a broad patient population.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Mar 2024 | $240M | — | SR One · Adage Capital · OrbiMed · Janus Henderson Investors | ↗ |
| POST IPO EQUITYOther financing | Apr 2022 | $230M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$113M | — |
| 2025 | $0 | — | −$113M | — |
| 2024 | $0 | — | −$119M | — |
| 2023 | $0 | — | −$126M | — |
| 2022 | $0 | — | −$119M | — |
| 2021 | $0 | — | −$86M | — |
| 2020 | $0 | — | −$91M | — |
Growth signals
Latest recorded traffic for Nkarta Therapeutics is 5.4K monthly website visits, down 16.9% over the last three months. Nkarta Therapeutics's team grew 5.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nkarta Therapeutics in the South San Francisco ecosystem
The Nkarta Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Novo Seeds
NEASR One
Novo Holdings
Samsara BioCapital
EQT Life Sciences
Amgen Ventures
RA Capital Management
Logos Capital
Series B and later8 investors entered at this stage
Adage Capital
OrbiMedJanus Henderson Investors
EcoR1 Capital
Commodore Capital
Cormorant Asset Management
Ridgeback Capital
Boxer Capital
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nkarta Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nkarta Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










